Amplius Wealth Advisors LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Amplius Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,234 shares of the company’s stock after buying an additional 727 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $757,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Wescott Financial Advisory Group LLC boosted its stake in shares of Johnson & Johnson by 50.5% in the second quarter. Wescott Financial Advisory Group LLC now owns 16,637 shares of the company’s stock valued at $2,432,000 after purchasing an additional 5,581 shares during the period. Zurich Insurance Group Ltd FI boosted its stake in shares of Johnson & Johnson by 366.6% in the second quarter. Zurich Insurance Group Ltd FI now owns 145,105 shares of the company’s stock valued at $21,209,000 after purchasing an additional 114,005 shares during the period. Fred Alger Management LLC boosted its stake in shares of Johnson & Johnson by 6.1% in the second quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock valued at $6,280,000 after purchasing an additional 2,488 shares during the period. Toronto Dominion Bank boosted its stake in shares of Johnson & Johnson by 13.0% in the second quarter. Toronto Dominion Bank now owns 1,197,314 shares of the company’s stock valued at $174,999,000 after purchasing an additional 137,292 shares during the period. Finally, Trinity Legacy Partners LLC boosted its stake in shares of Johnson & Johnson by 5.7% in the second quarter. Trinity Legacy Partners LLC now owns 31,616 shares of the company’s stock valued at $4,621,000 after purchasing an additional 1,699 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $145.39 on Thursday. The firm’s fifty day simple moving average is $148.26 and its 200-day simple moving average is $156.12. The stock has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is 71.78%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Bank of America reduced their target price on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday, January 17th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $173.27.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.